Skip to main content

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Terminated · Phase 2, Phase 3 · NCT04695977

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma

At a glance

Research payments reported, 2025
$86,575
U.S. investigators named
4
Sites paid
4
Planned or actual enrollment
20

About the trial

Sponsor
Regeneron Pharmaceuticals (with Bristol-Myers Squibb)
Tested
CMP-001 (drug), Nivolumab (drug)
Dates
Started 2021-02-24; completion 2024-07-22
Results posted
Yes

CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to participants with unresectable or metastatic melanoma. The study is divided into two phases: Phase 2 and Phase 3. The primary objective of Phase 2 of the study is to determine confirmed objective response rate (ORR) for treatment with first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma. The secondary objective of Phase 2 of the study is to evaluate the safety and tolerability of first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects wit…

From ClinicalTrials.gov, last updated 2026-06-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $86,575 in research payments for this study in 2025 (39 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.